Top

Published in:

01-05-2014 | Original Article

Muscle MRI in patients with long-chain fatty acid oxidation disorders

Authors: Eugene F. Diekman, W. Ludo van der Pol, Rutger A. J. Nievelstein, Sander M. Houten, Frits A. Wijburg, Gepke Visser

Published in: Journal of Inherited Metabolic Disease | Issue 3/2014

Abstract

Introduction

Muscle magnetic resonance imaging (MRI) is a useful tool for visualizing abnormalities in neuromuscular disorders. The value of muscle MRI has not been studied in long-chain fatty acid oxidation (lcFAO) disorders. LcFAO disorders may present with metabolic myopathy including episodic rhabdomyolysis.

Objective

To investigate whether lcFAO disorders are associated with muscle MRI abnormalities.

Methods

Lower body MRI was performed in 20 patients with lcFAO disorders, i.e. three carnitine palmitoyltransferase 2 deficiency (CPT2D), 12 very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), three mitochondrial trifunctional protein deficiency (MTPD) and two isolated long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHADD).

Results

At the time of MRI, four patients had muscle weakness, 14 had muscle pain and 13 were exercise intolerant. Median creatine kinase (CK) level of patients at the day of MRI was 398 U/L (range 35-12,483). T1W and STIR signal intensity (SI) were markedly increased in MTPD patients from girdle to lower leg. VLCADD patients showed predominantly proximal T1W SI changes, whereas LCHADD patients mostly showed distal T1W SI changes. Prominent STIR weighted signal intensity increases of almost all muscle groups were observed in patients with VLCADD and LCHADD with very high CK (>11.000) levels.

Conclusions and relevance

lcFAO disorders are associated with specific patterns of increased T1W and STIR signal intensity. These patterns may reflect lipid accumulation and inflammation secondary to lcFAO defects and progressive muscle damage. Future studies are needed to investigate whether muscle MRI might be a useful tool to monitor disease course and to study pathogenesis of lcFAO related myopathy.

Available only for authorised users

Adams EM, Chow CK, Premkumar A, Plotz PH (1995) The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 15:563–574PubMedCrossRef

Andresen BS, Olpin S, Poorthuis BJ et al (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64:479–494. doi:10.1086/302261 PubMedCentralPubMedCrossRef

Bakermans AJ, Geraedts TR, van Weeghel M et al (2011) Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by impaired left ventricular function. Circulation: Cardiovasc Imaging 4:558–565. doi:10.1161/CIRCIMAGING.111.963751

Boneh A, Andresen BS, Gregersen N et al (2006) VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 88:166–170. doi:10.1016/j.ymgme.2005.12.012 PubMedCrossRef

Carlier R-Y, Laforêt P, Wary C et al (2011) Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul Disord. doi:10.1016/j.nmd.2011.06.748

Chung KW, Suh BC, Shy ME et al (2008) Different clinical and magnetic resonance imaging features between Charcot-Marie-Tooth disease type 1A and 2A. Neuromuscul Disord 18:610–618. doi:10.1016/j.nmd.2008.05.012 PubMedCrossRef

Ciapaite J, Van Eikenhorst G, Bakker SJL et al (2005) Modular kinetic analysis of the adenine nucleotide translocator-mediated effects of palmitoyl-CoA on the oxidative phosphorylation in isolated rat liver mitochondria. Diabetes 54:944–951PubMedCrossRef

Costa AF, Di Primio GA, Schweitzer ME (2012) Magnetic resonance imaging of muscle disease: A pattern-based approach. Muscle Nerve 46:465–481. doi:10.1002/mus.23370 PubMedCrossRef

Cox FM, Reijnierse M, van Rijswijk CSP et al (2011) Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 50:1153–1161. doi:10.1093/rheumatology/ker001 CrossRef

Degardin A, Morillon D, Lacour A et al (2010) Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skelet Radiol 39:1219–1227. doi:10.1007/s00256-010-0930-4 CrossRef

Diekman E, Boelen CA, Prinsen HCMT et al (2013) Necrotizing enterocolitis and respiratory distress syndrome as first clinical presentation of mitochondrial trifunctional protein deficiency. JIMD Case Rep. doi:10.1007/8904_2012_128

Dlamini N, Jan W, Norwood F et al (2008) Muscle MRI findings in siblings with juvenile-onset acid maltase deficiency (Pompe disease). Neuromuscul Disord 18:408–409. doi:10.1016/j.nmd.2008.02.006 PubMedCrossRef

Gardner-Medwin JMM, Irwin G, Johnson K (2009) MRI in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis. Ann N Y Acad Sci 1154:52–83. doi:10.1111/j.1749-6632.2009.04498.x PubMedCrossRef

Halperin ML, Robinson BH, Fritz IB (1972) Effects of palmitoyl CoA on citrate and malate transport by rat liver mitochondria. Proc Natl Acad Sci U S A 69:1003–1007PubMedCentralPubMedCrossRef

Houten SM, Wanders RJA (2010) A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis 33:469–477. doi:10.1007/s10545-010-9061-2 PubMedCentralPubMedCrossRef

Joe AWB, Yi L, Natarajan A et al (2010) Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 12:153–163. doi:10.1038/ncb2015 PubMedCrossRef

Kim HK, Laor T, Horn PS, Wong B (2010) Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol 11:304–311. doi:10.3348/kjr.2010.11.3.304 PubMedCentralPubMedCrossRef

Kinali M, Arechavala-Gomeza V, Cirak S et al (2011) Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 76:346–353. doi:10.1212/WNL.0b013e318208811f PubMedCentralPubMedCrossRef

Laforêt P, Vianey-Saban C (2010) Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 20:693–700. doi:10.1016/j.nmd.2010.06.018 PubMedCrossRef

Laforêt P, Acquaviva-Bourdain C, Rigal O et al (2009) Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 19:324–329. doi:10.1016/j.nmd.2009.02.007 PubMedCrossRef

Lindner M, Hoffmann GF, Matern D (2010) Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 33:521–526. doi:10.1007/s10545-010-9076-8 PubMedCrossRef

McHugh DMS, Cameron CA, Abdenur JE et al (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 13:230–254. doi:10.1097/GIM.0b013e31820d5e67 PubMedCrossRef

Mercuri E, Jungbluth H, Muntoni F (2005) Muscle imaging in clinical practice: diagnostic value of muscle magnetic resonance imaging in inherited neuromuscular disorders. Curr Opin Neurol 18:526–537PubMedCrossRef

Mercuri E, Pichiecchio A, Allsop J et al (2007) Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 25:433–440. doi:10.1002/jmri.20804 PubMedCrossRef

Morel F, Lauquin G, Lunardi J et al (1974) An appraisal of the functional significance of the inhibitory effect of long chain acyl-CoAs on mitochondrial transports. FEBS Lett 39:133–138PubMedCrossRef

Murphy WA, Totty WG, Carroll JE (1986) MRI of normal and pathologic skeletal muscle. AJR Am J Roentgenol 146:565–574PubMedCrossRef

Pareyson D, Marchesi C (2009) Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 8:654–667. doi:10.1016/S1474-4422(09)70110-3 PubMedCrossRef

Pichiecchio A, Uggetti C, Ravaglia S et al (2004) Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord 14:51–55PubMedCrossRef

Purevsuren J, Fukao T, Hasegawa Y et al (2009) Clinical and molecular aspects of Japanese patients with mitochondrial trifunctional protein deficiency. Mol Genet Metab 98:372–377. doi:10.1016/j.ymgme.2009.07.011 PubMedCrossRef

Rodeheffer MS (2010) Tipping the scale: muscle versus fat. Nat Cell Biol 12:102–104. doi:10.1038/ncb0210-102 PubMedCrossRef

Schulze M, Kötter I, Ernemann U et al (2009) MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol 192:1708–1716. doi:10.2214/AJR.08.1764 PubMedCrossRef

Shchelochkov O, Wong L-J, Shaibani A, Shinawi M (2009) Atypical presentation of VLCAD deficiency associated with a novel ACADVL splicing mutation. Muscle Nerve 39:374–382. doi:10.1002/mus.21157 PubMedCrossRef

Spiekerkoetter U (2010) Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 33:527–532. doi:10.1007/s10545-010-9090-x PubMedCrossRef

Tzaribachev N, Well C, Schedel J, Horger M (2009) Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 29:1511–1514. doi:10.1007/s00296-009-0890-y PubMedCrossRef

Uezumi A, Fukada S-I, Yamamoto N et al (2010) Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 12:143–152. doi:10.1038/ncb2014 PubMedCrossRef

Vaartjes WJ, Kemp A, Souverijn JHM, van den Bergh SG (1972) Inhibition by fatty acyl esters of adenine nucleotide translocation in rat-liver mitochondria. FEBS Lett 23:303–308PubMedCrossRef

Ventura FV, Ruiter JP, Ijlst L et al (1995) Inhibition of oxidative phosphorylation by palmitoyl-CoA in digitonin permeabilized fibroblasts: implications for long-chain fatty acid beta-oxidation disorders. Biochim Biophys Acta 1272:14–20PubMedCrossRef

Ventura FV, Ruiter J, Ijlst L et al (2005) Differential inhibitory effect of long-chain acyl-CoA esters on succinate and glutamate transport into rat liver mitochondria and its possible implications for long-chain fatty acid oxidation defects. Mol Genet Metab 86:344–352. doi:10.1016/j.ymgme.2005.07.030 PubMedCrossRef

Vianey-Saban C, Divry P, Brivet M et al (1998) Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 269:43–62PubMedCrossRef

Viddeleer AR, Sijens PE, van Ooyen PMA et al (2012) Sequential MR imaging of denervated and reinnervated skeletal muscle as correlated to functional outcome. Radiology 264:522–530. doi:10.1148/radiol.12111915 PubMedCrossRef

Violante S, IJLst L, van Lenthe H et al (2010) Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. Biochim Biophys Acta 1802:728–732. doi:10.1016/j.bbadis.2010.06.002 PubMedCrossRef

Wanders RJA, Ruiter JPN, IJLst L et al (2010) The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis 33:479–494. doi:10.1007/s10545-010-9104-8 PubMedCentralPubMedCrossRef

Wattjes MP, Kley RA, Fischer D (2010) Neuromuscular imaging in inherited muscle diseases. Eur Radiol 20:2447–2460. doi:10.1007/s00330-010-1799-2 PubMedCentralPubMedCrossRef

Title: Muscle MRI in patients with long-chain fatty acid oxidation disorders
Authors: Eugene F. Diekman
W. Ludo van der Pol
Rutger A. J. Nievelstein
Sander M. Houten
Frits A. Wijburg
Gepke Visser
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2014
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-013-9666-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusions and relevance

Please log in to get access to this content

Other articles of this Issue 3/2014

Increased aortic stiffness and blood pressure in non-classic Pompe disease

Erratum to: Concordance rates of Wilson’s disease phenotype among siblings

Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease

Update on transcobalamin deficiency: clinical presentation, treatment and outcome

Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency

Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials